Advances in Large-Scale Biomanufacturing
“This new ASM Press study provides a clear view of what the ‘industry’ perceives to be the future of biopharmaceutical manufacturing”
Coverage
- 1,224 Pages
- 94 authors
- 34 Chapters
- 18 Reviewers
- 290 Figures & Tables
- 1,345 References
A Comprehensive Study of the Science, Technology and Business of Biopharmaceutical Manufacturing. Published by the ASM Press [American Society for Microbiology Press] and BioPlan Associates, Inc., November 2007.
Download Table of Contents 700k PDF
- Frontiers in Bioprocessing: 2007
- The Science for Biogenerics: Are We There Already?
- Maximizing Productivity in Biopharmaceutical Manufacturing
- Increasing Performance of Mammalian Expression Platforms
- Cell Line Engineering and Development: Case Studies
- Design of Large-Scale Cell Culture Process
- Challenges in Biopharmaceutical Scale-up to Production
- Large-Scale Microbial Production Technology for Human Therapeutic Products
- Microbiological Methods in Support of Manufacturing
- Initial Protein Recovery Process
- The Scaling Up of Fermentation and Primary Recovery Processes of Soluble Protein Antigens
- Scale-up of Saccharomyces cerevisiae Fermentation
- Good Automation Manufacturing Practice (GAMP)
- Advances in Improved Expression of Recombinant Proteins in Microbial Systems
- Design of Large-Scale Cell Culture Process —A Process Engineering Point of View
- Protein Stability, Solubility and Solute Interactions
- Launching New Biologics: A Process and Facility Design Approach
- Disposable Technologies for Manufacturing of Biologics
- Managing Large Volume, Single Use Disposables
- Optimization of Antibody Processing: Upstream and Downstream
- Simulated Moving Bed Chromatography
- Implementation of Membrane Technology in Antibody Large-Scale Purification
- Development of Viral Clearance Strategies for Large-Scale Monoclonal Antibody Production
- Downstream Processing: Removing Economic and Technical Bottlenecks
- Purification of Monoclonal and Genetically Engineered Antibodies
- Regulatory Environment for Follow-on Biologics
- Post-Approval Changes for Large Scale Biopharmaceutical Manufacturing: Global
- FDA and Regulatory Issues in Biopharmaceutical Manufacturing
- Strategic Issues: Capital Investments
- Pricing Issues for Biotechnology Products
- Economics of Scheduling, De-bottlenecking, and Cycle Time
- Intellectual Property Considerations in Scale-Up of Biomanufacturing Processes
- Forecasting Industry-wide Biopharmaceutical Manufacturing Capacity Requirements
- Worldwide Therapeutic Protein Production Capacity
- Accelsiors Group International
- Advanced Scientifics Inc.
- Amgen, Inc.
- Amgen, Inc.
- Amgen, Inc.
- Amgen, Inc.
- Amgen, Inc.
- Biogen IDEC
- Biomanufacturing Training and Education Center
- BioPharm Services UK
- BioProcess Technology
- Biotechnology Unit, NIDDK, NIH
- Bristol Myers Squibb
- Chromos, Burnaby, BC
- Cambrex Bio Science
- Clonex Development, Inc.
- Consultants Inc.
- Eli Lilly & Co.
- Eli Lilly & Co.
- Eli Lilly & Co.
- Eli Lilly & Co.
- Excellent Pharma Consulting
- Falconridge Associates
- Fluor Corporation/Fluor Daniel Inc.
- Fluor Corporation/Fluor Daniel Inc.
- Fluor Corporation/Fluor Daniel Inc.
- GE Healthcare
- Human Genome Sciences
- Institute for Chemical and Bioengineering
- Intelligen, Inc.
- Johns Hopkins University
- Magneticals
- Max Planck Institute
- Medical Marketing Economics, LLC
- Medimmune
- Merck & Co., Inc.
- Merck Research Laboratories
- Merck Research Laboratories
- Morphotek
- NC State University
- ncBIOsource
- Newport Biotech Consultants
- Newport Consulting
- Novavax Inc
- Novozymes Delta Limited
- PD-Direct Services
- Protein Sciences Corp
- SAIC, National Cancer Institute
- Sanofi Pasteur
- Sartorius AG, Germany
- Schwegman Lundberg Woessner & Kluth
- Scios Inc.
- Seattle Genetics
- Strategic Manufacturing Worldwide, Inc.
- TLG Consulting Inc.
- Université Clermont
- Vectech Pharmaceutical Consultants, Inc.
